<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Antepartum care of pregnant patients with symptomatic infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Antepartum care of pregnant patients with symptomatic infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Antepartum care of pregnant patients with symptomatic infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brenna L Hughes, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4122931596"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnant people with COVID-19 may be asymptomatic or symptomatic. Symptomatic patients appear to be at increased risk for developing severe sequelae of the disease compared with nonpregnant reproductive-aged females. They also may be at increased risk for developing some pregnancy complications (eg, preterm birth) compared with uninfected or asymptomatic pregnant people. The clinical care of symptomatic patients depends on illness severity, underlying medical comorbidities that increase the risk for severe disease, coexistent pregnancy complications, and social situation (eg, ability for self-care and follow-up).</p><p>This topic will discuss the antepartum care of pregnant people with symptomatic COVID-19. An overview of issues related to COVID-19 in pregnancy and management of labor, birth, and postpartum care are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues"</a> and  <a class="medical medical_review" href="/z/d/html/129846.html" rel="external">"COVID-19: Intrapartum and postpartum issues"</a>.)</p><p class="headingAnchor" id="H1050265044"><span class="h1">INITIAL EVALUATION OF SYMPTOMATIC PATIENTS</span><span class="headingEndMark"> — </span>The initial evaluation (by telehealth and/or in person) of patients with COVID-19 should focus on:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of symptoms (eg, types, duration, severity)  (<a class="graphic graphic_table graphicRef127890" href="/z/d/graphic/127890.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of risk factors for severe illness  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 2</a>)</p><p></p><p>Initial evaluation and risk stratification of all adult pregnant or nonpregnant patients with COVID-19, including assessment of dyspnea and oxygenation, need for/site of in-person assessment, and consideration of COVID-19 specific therapy, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and <a class="local">'Use of antiviral therapy'</a> below.)</p><p>Although it is desirable see all patients at high risk for severe disease in person, this may not always be possible during a surge when patient volume exponentially increases. In our practice, at a minimum, we have in-person visits for those who are &gt;36 weeks of gestation and those who need antenatal testing.</p><p class="headingAnchor" id="H2635742455"><span class="h1">CANDIDATES FOR HOSPITALIZATION</span><span class="headingEndMark"> — </span>Inpatient monitoring and care are appropriate for patients with severe or critical illness. Specific criteria for hospitalization may vary with the availability of hospital resources and patient-specific clinical and/or social factors that might support earlier hospitalization, but typically include the following characteristics of severe disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen saturation (SpO<sub>2</sub>) &lt;94 percent on room air</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory rate &gt;30 breaths/minute</p><p class="bulletIndent1"><span class="glyph">●</span>Pressure of oxygen (PaO<sub>2</sub>)/fraction of inspired oxygen (FiO<sub>2</sub>) &lt;300 mmHg</p><p class="bulletIndent1"><span class="glyph">●</span>Lung infiltrates &gt;50 percent</p><p></p><p>Pregnant hospitalized patients with severe or critical disease or an oxygen requirement plus comorbidities should be cared for by a multispecialty team at a level III or IV hospital with obstetric services and an adult intensive care unit (ICU) [<a href="#rid1">1,2</a>]. This team can help determine the most appropriate location (medical or obstetric ward, labor and delivery unit, or ICU). COVID-19 status alone is not necessarily a reason to transfer noncritically ill pregnant patients with suspected or confirmed COVID-19.</p><p class="headingAnchor" id="H3647226538"><span class="h1">INPATIENT EVALUATION AND CARE</span></p><p class="headingAnchor" id="H2244981142"><span class="h2">Inpatient evaluation</span><span class="headingEndMark"> — </span>The objective in the evaluation of hospitalized patients with COVID-19 is to evaluate for features associated with severe illness  (<a class="graphic graphic_table graphicRef127820" href="/z/d/graphic/127820.html" rel="external">table 3</a>) and identify organ dysfunction or other comorbidities that could complicate potential therapy. The laboratory and imaging evaluation is the same for pregnant and nonpregnant patients. However, it is important to note that several of the features associated with severe illness in the table are not reliable in pregnancy (C-reactive protein and D-dimer are increased in normal pregnancy  (<a class="graphic graphic_table graphicRef81137" href="/z/d/graphic/81137.html" rel="external">table 4</a>)) and should not be used for consideration of risk of severe disease. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Evaluation'</a>.)</p><p>A portable chest radiograph is sufficient for initial evaluation of pulmonary complications and extent of lung involvement in hospitalized patients with COVID-19. A single chest radiograph carries a very low fetal radiation dose of 0.0005 to 0.01 milligray (mGy). Computed tomography (CT) should be performed, if clinically indicated, as the fetal radiation dose for a routine chest CT  (<a class="graphic graphic_table graphicRef75594" href="/z/d/graphic/75594.html" rel="external">table 5</a>) is also low and not associated with an increased risk of fetal anomalies or pregnancy loss (see  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>). Some authorities have advocated lung ultrasound, possibly at the same time as the obstetric scan, for quick diagnosis of pneumonia in symptomatic pregnant people [<a href="#rid3">3,4</a>]. A detailed description for performing lung ultrasound, which appears to have good diagnostic accuracy and has fewer infection control implications than CT [<a href="#rid5">5</a>], can be found elsewhere [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Lung ultrasound'</a>.)</p><p class="headingAnchor" id="H2118166957"><span class="h2">Inpatient care</span></p><p class="headingAnchor" id="H4287979873"><span class="h3">Overview</span><span class="headingEndMark"> — </span>General management of hospitalized adults involves [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of empiric, prophylactic, and therapeutic drugs. Issues to consider include empiric treatment of influenza or bacterial pneumonia, prevention of venous thromboembolism (VTE), and management of chronic medications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of hypoxemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of complications (eg, acute respiratory distress syndrome [ARDS], arrhythmias and other cardiac disorders, kidney injury)</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/z/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)"</a>.)</p><p>The management of ARDS in patients with COVID-19 and other critical care issues are discussed elsewhere  (<a class="graphic graphic_table graphicRef127595" href="/z/d/graphic/127595.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p>Specific issues related to pregnancy are addressed in the following section and summarized in the table  (<a class="graphic graphic_table graphicRef133124" href="/z/d/graphic/133124.html" rel="external">table 7</a>).</p><p class="headingAnchor" id="H2280144166"><span class="h3">Selected issues in the management of hospitalized pregnant patients</span><span class="headingEndMark"> — </span>The following considerations apply specifically to pregnant patients.</p><p class="headingAnchor" id="H2590115001"><span class="h4">Target SpO2</span><span class="headingEndMark"> — </span>Many experts suggest maintaining maternal peripheral oxygen saturation (SpO<sub>2</sub>) at ≥95 percent, which is in excess of maternal oxygen needs [<a href="#rid7">7,8</a>]. If SpO<sub>2</sub> falls below 95 percent, an arterial blood gas may be obtained to measure the partial pressure of oxygen (PaO<sub>2</sub>): Maternal PaO<sub>2</sub> greater than 70 mmHg is desirable to maintain a favorable oxygen diffusion gradient from the maternal to the fetal side of the placenta. The World Health Organization (WHO) suggests maintaining maternal SpO<sub>2 </sub>≥92 to 95 percent once the patient is stable [<a href="#rid9">9</a>]. Others have proposed maintaining SpO<sub>2</sub> between 92 and 96 percent for patients with acute respiratory failure who require supplemental O<sub>2</sub>, as long as fetal status is reassuring, because a lower target SpO<sub>2</sub> may prevent unnecessary invasive interventions [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3527340615"><span class="h4">Respiratory support</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prone position</strong> — In the intensive care unit (ICU), severely ill patients with COVID-19 are often managed in the prone position; the left lateral position is an alternative but may not be as effective. Some ICUs have extended this approach to pregnant patients, although even a semiprone position can be a difficult position in which to place a pregnant person in the last half of pregnancy [<a href="#rid11">11-13</a>]. Padding above and below the uterus &gt;24 weeks size is desirable to avoid aortocaval compression [<a href="#rid11">11,14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other respiratory support measures</strong> – Noninvasive respiratory support of the critically ill COVID-19 patient, timing and procedure of intubation, and management of the hospitalized and the intubated patient are reviewed separately. Most aspects of these interventions are identical for pregnant and nonpregnant patients. An exception is that minute ventilation generally should be adjusted to maintain the PaCO<sub>2</sub> between 30 to 32 mmHg because significant respiratory alkalosis may decrease uterine blood flow. However, if indicated, limited data suggest that permissive hypercapnia (partial pressure of carbon dioxide [PCO<sub>2</sub>] &lt;60 mmHg) does not appear to be harmful to the fetus. High positive end-expiratory pressure strategies (&gt;10 mmHg), if considered, require close ongoing maternal and fetal monitoring because they decrease preload and cardiac output [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/131226.html" rel="external">"COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)"</a> and  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p></p><p class="bulletIndent1">Limited data are available regarding critically ill pregnant patients with COVID-19. In one study of 91 such patients, lung mechanics and ventilatory parameters were similar to those in the nonpregnant population with COVID-19 [<a href="#rid15">15</a>]. The Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score was the only risk factor for invasive mechanical ventilation. Delivery in 47 patients did not improve ventilatory parameters associated with mortality in ARDS patients, other than the arterial oxygen tension (PaO<sub>2</sub>) to fraction of inspired oxygen (FiO<sub>2</sub>) ratio.</p><p></p><p class="bulletIndent1">In refractory COVID-19-related respiratory failure, maternal ECMO may be necessary and delivery on ECMO can be performed safely [<a href="#rid13">13,16-19</a>]. If ECMO is not available, transporting the patient to a facility where it is available should be considered. Both femoral and jugular cannulation sites have been used in pregnancy. In a meta-analysis evaluating outcomes of 386 pregnant patients with acute respiratory distress syndrome secondary to critical COVID-19 treated with ECMO, the maternal survival rate was 75.6 percent (95% CI 66.0-84.1) and the live birth rate was 83.7 percent (95% CI 76.8-89.6); approximately 5 percent of patients miscarried and 10 percent had a stillbirth [<a href="#rid20">20</a>]. Serious maternal morbidity included venous thromboembolism (37 percent), acute kidney injury (20 percent), cardiac complications (18 percent), and stroke/intracranial hemorrhage (7 percent). (See  <a class="medical medical_review" href="/z/d/html/127765.html" rel="external">"COVID-19: Extracorporeal membrane oxygenation (ECMO)"</a>.)</p><p></p><p class="headingAnchor" id="H2563209370"><span class="h4">Venous thromboembolism prophylaxis</span><span class="headingEndMark"> — </span>Prophylactic-dose anticoagulation is recommended for pregnant patients hospitalized because of COVID-19, if there are no contraindications to its use, and generally discontinued when the patient is discharged to home. Intermittent pneumatic compression is suggested when pharmacologic prophylaxis is contraindicated. </p><p><a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">Unfractionated heparin</a> (UFH) is generally preferred for pregnant patients who might be proximate to delivery because it is more readily reversed than low molecular weight heparin (LMWH). For these patients and those who have a contraindication to LMWH, we suggest low or intermediate UFH dose  (<a class="graphic graphic_table graphicRef140440" href="/z/d/graphic/140440.html" rel="external">table 8</a>). For pregnant patients who are unlikely to be delivered within a few days, we suggest low- or intermediate-dose LMWH  (<a class="graphic graphic_table graphicRef140440" href="/z/d/graphic/140440.html" rel="external">table 8</a>). More information on anticoagulation dosing during pregnancy is available separately. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Low and intermediate dose (used for VTE prophylaxis)'</a>.)</p><p>Pregnant outpatients with COVID-19 and those who are asymptomatic or mildly symptomatic and hospitalized for reasons other than COVID-19 (eg, labor, preterm prelabor rupture of membranes) do not require anticoagulation, unless antithrombotic therapy had been prescribed during pregnancy for another indication (eg, previous VTE). They should be encouraged to stay hydrated and ambulate. Decisions regarding VTE prophylaxis should be individualized, considering concomitant VTE risk factors and, in postpartum patients, mode of delivery. (See  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a> and  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>.)</p><p>We do not prescribe low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for individuals with COVID-19 except for standard indications (preeclampsia prophylaxis). Aspirin does not appear to improve COVID-19 outcomes.</p><p class="headingAnchor" id="H1439562417"><span class="h5">Risk of VTE</span><span class="headingEndMark"> — </span>Direct data on risk of VTE related to COVID-19 are limited but suggest an increased risk in infected pregnant and postpartum patients compared with uninfected pregnant and postpartum patients (eg, 1.0 versus 0.5 percent; adjusted hazard ratio [HR] 2.62, 95% CI 1.60-4.29 in one national study including over 2400 infected individuals [<a href="#rid21">21</a>]) [<a href="#rid21">21-25</a>]. Pregnancy, reduced mobility, and dehydration can contribute to this risk. In a systematic review including &gt;1000 pregnant patients with COVID-19, there were three cases of venous thrombosis (0.28 percent, 95% CI 0.0-0.6), one case of arterial thrombosis, seven cases of disseminated intravascular coagulation (DIC; 0.66 percent, 95% CI 0.17-1.1), and a further three cases of coagulopathy without meeting the criteria for DIC (0.28 percent, 95% CI 0.0-0.6) [<a href="#rid26">26</a>]. </p><p></p><p>VTE occurs primarily in hospitalized patients with severe or critical illness: in one series of 1219 pregnant patients with COVID-19, the incidence of VTE was 6 percent (95% CI 2-11) among those with severe-critical illness, 0.2 percent with mild-moderate illness, and 0 in asymptomatic patients [<a href="#rid23">23</a>]. In another series, 4.4 percent of 91 pregnant/postpartum patients with severe infection experienced VTE [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H2721161700"><span class="h4">Use of dexamethasone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> 6 mg daily for up to 10 days or until discharge is recommended for severely ill nonpregnant patients who are on supplemental oxygen or ventilatory support. Glucocorticoids may also have a role in the management of refractory shock in critically ill patients with COVID-19. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'</a>.)</p><p>In pregnant patients who meet criteria for use of glucocorticoids for maternal treatment of COVID-19 and also meet criteria for use of antenatal corticosteroids to induce fetal maturity, we suggest:</p><p class="bulletIndent1"><span class="glyph">●</span>Administer the usual doses of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (four doses of 6 mg intravenously 12 hours apart) to induce fetal maturation, and</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continue maternal treatment to complete the course of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (6 mg orally or intravenously daily for 10 days or until discharge, whichever is shorter)</p><p></p><p>Our approach is the same as that of the Society for Maternal-Fetal Medicine [<a href="#rid8">8</a>]. After the initial four doses of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, WHO guidelines switch to <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> to minimize fetal glucocorticoid exposure beyond the standard used for fetal lung maturation [<a href="#rid27">27</a>].</p><p>Glucose levels should be monitored closely in patients with gestational or pregestational diabetes as hyperglycemia will usually occur after administration of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. Monitoring and treatment of hyperglycemia are the same as in patients with diabetes at risk for preterm birth who receive a course of antenatal corticosteroids to induce fetal maturity, and described separately. (See  <a class="medical medical_review" href="/z/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management", section on 'Antenatal glucocorticoids in patients at risk for preterm birth'</a>.)</p><p>In patients without diabetes, the need for glucose monitoring is unclear, but frequent maternal glucose levels &gt;180 mg/dL (10 mmol/L) are undesirable as they lead to fetal hyperglycemia and hyperinsulinemia, which increase fetal oxygen requirements.</p><p>Criteria for glucocorticoid administration in COVID-19 and efficacy data for different steroids are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'</a>.)</p><p class="headingAnchor" id="H2143768586"><span class="h4">Use of NSAIDs and acetaminophen</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs) can be administered to COVID-19 patients when clinically indicated. The lowest effective dose is used, ideally for less than 48 hours and guided by gestational age-related potential fetal toxicity (eg, oligohydramnios, premature closure of the ductus arteriosus). Low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for prevention of preeclampsia is safe throughout pregnancy. (See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Fetal side effects'</a> and  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p>We use <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> as the preferred antipyretic and analgesic agent, if possible. In patients with abnormal liver chemistries secondary to COVID-19, hepatic toxicity is a potential concern of acetaminophen use. However, doses less than 2 grams per day are likely safe in the absence of severe or decompensated hepatic disease. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'NSAID use'</a>.)</p><p>Use of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> in pregnancy, including in the first trimester, has been shown overall to be safe and may attenuate the pregnancy risks associated with fever exposure. Hyperthermia, which is common in COVID-19, is a theoretical concern as elevation of maternal core temperature from a febrile illness during organogenesis in the first trimester may be associated with an increased risk of congenital anomalies, especially neural tube defects, or miscarriage; however, an increased incidence of these outcomes has not been observed. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management", section on 'Fever/hyperthermia'</a>.)</p><p class="headingAnchor" id="H4005763233"><span class="h4">COVID-19-specific treatments</span><span class="headingEndMark"> — </span>Selection of COVID-19-specific therapy for adults who have severe disease requiring oxygen supplementation is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef134578" href="/z/d/graphic/134578.html" rel="external">algorithm 1</a>). The safety, efficacy, and use of antiviral and other drugs for treatment of COVID-19 is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'COVID-19-specific therapy'</a>.)</p><p>Very few trials of drugs for treatment of COVID-19 have included pregnant people (eg, SOLIDARITY trial [<a href="#rid28">28</a>], RECOVERY trial [<a href="#rid29">29</a>]). Decisions about use of COVID-19-specific therapies during pregnancy should involve shared decision-making, considering severity of maternal status, underlying risk factors, gestational age, potential maternal benefit, likelihood of placental transfer and potential mechanisms for fetal harm, and lack of information on fetal and newborn risks. The following drugs may be used in hospitalized patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remdesivir</strong> – <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">Remdesivir</a> is a novel nucleotide analog that inhibits RNA-dependent RNA polymerase. No data are available on placental transfer in humans. Data on pregnancy outcomes in patients with COVID-19 treated with remdesivir are limited and confounded by the severity of disease and disease complications in these patients [<a href="#rid30">30</a>]. It has also been used in pregnancy without reported fetal toxicity in some patients with Ebola and Marburg virus disease [<a href="#rid31">31</a>]. We offer treatment with remdesivir when indicated. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Remdesivir'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baricitinib</strong>, <strong>tofacitinib</strong> – Placental transfer of <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> (a Janus kinase [JAK] inhibitor) may be expected based on its molecular weight. Information on use of baricitinib in pregnancy is limited to a case report and registry data of inadvertent administration during pregnancy [<a href="#rid32">32</a>]. These limited human data are insufficient to inform a drug-associated risk for major congenital anomalies or miscarriage. Embryo-fetal toxicity, such as skeletal anomalies and reduced fertility, have been observed in animals dosed in excess of the maximum human exposure. We generally offer treatment with baricitinib when indicated in pregnancy after a risk-benefit discussion.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> is another JAK inhibitor and similar considerations apply. The drug has been used in 33 pregnancies for non-COVID-19 disorders and pregnancy outcomes were similar to the general population [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Baricitinib and JAK inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tocilizumab</strong><strong>, </strong><strong>sarilumab</strong><strong>, </strong><strong>siltuximab</strong><strong>, </strong><strong>anakinra</strong> – Markedly elevated inflammatory markers (eg, D-dimer, ferritin) and elevated pro-inflammatory cytokines (including interleukin [IL]-6) are associated with critical and fatal COVID-19, and blocking the inflammatory pathway may prevent disease progression [<a href="#rid34">34</a>]. Several agents that target the IL-6 pathway have been evaluated in randomized trials for treatment of COVID-19; these include the IL-6 receptor blockers <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> and <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">sarilumab</a>, the direct IL-6 inhibitor <a class="drug drug_general" data-topicid="95045" href="/z/d/drug information/95045.html" rel="external">siltuximab</a>, and the interleukin-1 (IL-1) inhibitor <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a> is a recombinant humanized monoclonal IgG1 antibody that interrupts IL-6. A review of tocilizumab use in pregnancy included 610 cases (20 with COVID-19, most of the others for rheumatological diseases) and did not reveal clear serious safety signals, but the available data had significant limitations [<a href="#rid35">35</a>]. We generally offer treatment with tocilizumab when indicated in pregnancy after a risk-benefit discussion. Even less information is available about use of <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">sarilumab</a>, <a class="drug drug_general" data-topicid="95045" href="/z/d/drug information/95045.html" rel="external">siltuximab</a>, and <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> in pregnancy [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'</a> and <a class="local">'Use of antiviral therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H410743449"><span class="h4">Fetal monitoring</span><span class="headingEndMark"> — </span>A specific management issue in pregnant patients is monitoring fetuses who are at a gestational age at which delivery for fetal indications and neonatal resuscitation would be considered. The need for and frequency of fetal testing depend on gestational age, stability of maternal vital signs and oxygenation, other maternal comorbidities, and discussions with the patient and the family that consider the possibly increased risks of stillbirth and perinatal morbidities in the absence of testing.</p><p>Continuous fetal monitoring can be used in severely ill hospitalized patients in whom emergency cesarean birth would be performed for a persistent nonreassuring fetal heart rate pattern. An abnormal tracing might also help to guide adjustment of maternal oxygen therapy. </p><p>In patients with stable SpO<sub>2</sub>, a nonstress test can be performed once or twice daily, as one option.</p><p class="headingAnchor" id="H2899928411"><span class="h4">Monitoring for preterm labor</span><span class="headingEndMark"> — </span>Monitoring pregnant patients for signs and symptoms of preterm labor is a routine component of obstetric care and should be a component of maternal monitoring of pregnant patients admitted to nonobstetric hospital units. (See  <a class="medical medical_review" href="/z/d/html/6798.html" rel="external">"Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment"</a>.)</p><p class="headingAnchor" id="H74259493"><span class="h4">Length of isolation</span><span class="headingEndMark"> — </span>Guidelines for discontinuing isolation in the healthcare setting are summarized in the table  (<a class="graphic graphic_table graphicRef127962" href="/z/d/graphic/127962.html" rel="external">table 9</a>). (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p class="headingAnchor" id="H3784286327"><span class="h1">OUTPATIENT CARE OF PATIENTS WITH MILD OR MODERATE ILLNESS</span><span class="headingEndMark"> — </span>Most (at least 86 percent [<a href="#rid38">38</a>]) pregnant patients with known or suspected COVID-19 have mild disease (no shortness of breath) associated with the replication of SARS-CoV-2. Nonsevere disease does not warrant hospital-level care in the absence of obstetric problems, concern for rapid deterioration, inability to promptly return to the hospital, or, possibly, inability to self-isolate. It is important to note, however, that infection with SARS-CoV-2 may cause life-threatening illness in any patient, even among those without risk factors for severe or critical disease. Progression to the severe end of disease spectrum appears to be caused by a dysregulated immune/inflammatory response to SARS-CoV-2 that leads to tissue damage. (See  <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues", section on 'Classification of disease severity'</a>.)</p><p>In a prospective cohort study, 90 percent of 1326 COVID-19 infections diagnosed in pregnant patients from March 2020 to September 2021 were asymptomatic or mild; 10 percent of 436 initially asymptomatic patients developed symptoms; and of patients with asymptomatic or mild symptoms at diagnosis, 4 percent of first, 5 percent of second, and 6 percent of third-trimester patients developed moderate, severe, or critical illness [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H4017863802"><span class="h2">Home care</span><span class="headingEndMark"> — </span>Home care is generally supportive, similar to that advised for other acute viral illnesses. Hydration, adequate rest, and frequent ambulation with more advanced activity as soon as tolerated are advised. Specific issues discussed in detail separately include:</p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>supportive and medical care</strong> of ambulatory COVID-19 patients. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Symptom management and recovery expectation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Options for preferred <strong>over-the-counter medications</strong> in pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4793.html" rel="external">"Approach to the pregnant patient with a respiratory infection", section on 'The common cold'</a> and <a class="local">'Use of NSAIDs and acetaminophen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The importance of <strong>infection control and self-isolation </strong> (<a class="graphic graphic_algorithm graphicRef139926" href="/z/d/graphic/139926.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the home setting'</a>.)</p><p></p><p>Ideally, government and community organizations and social service agencies will provide dedicated housing units to isolate and care for patients experiencing homelessness.</p><p class="headingAnchor" id="H1054890869"><span class="h2">When to call the provider</span><span class="headingEndMark"> — </span>Outpatients should be followed closely for progression to severe or critical disease and given instructions for infection control, symptom management, warning symptoms, and obstetric follow-up (at least once within two weeks of COVID-19 diagnosis). In general, pregnant outpatients should call their provider (or seek emergency medical care) if they experience any of the following [<a href="#rid1">1,8,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening dyspnea (see  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting", section on 'Reevaluation for worsening clinical acuity'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory rate ≥20 to 24 breaths/minute and/or heart rate &gt;100 beats per minute</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen saturation (SpO<sub>2</sub>) &lt;95% (if the patient has access to an over-the-counter pulse oximeter)</p><p class="bulletIndent1"><span class="glyph">●</span>Unremitting fever &gt;39°C despite appropriate use of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to tolerate oral hydration and medications</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pleuritic chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Confusion or other alterations in mentation</p><p class="bulletIndent1"><span class="glyph">●</span>Obstetric complications (eg, preterm contractions, vaginal bleeding, rupture of membranes)</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased fetal movement</p><p></p><p class="headingAnchor" id="H3013400582"><span class="h2">Fetal monitoring</span><span class="headingEndMark"> — </span>COVID-19 alone is not considered an indication for nonstress tests or biophysical profiles. Stillbirth has been reported after maternal SARS-CoV-2 infection, but the association is unclear; unvaccinated patients in the first two weeks of the infection appear to be at higher risk, and the absolute risk appears to be low [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H1968307678"><span class="h2">Use of antiviral therapy</span><span class="headingEndMark"> — </span>Pregnant and recently pregnant patients with mild to moderate COVID-19 are potential candidates for COVID-19-specific therapy because they are at increased risk for progression to severe disease and treatment can substantially reduce this risk and hospitalization (and with some interventions, mortality). </p><p><a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">Nirmatrelvir-ritonavir</a> is our preferred therapy. We suggest it for pregnant patients with additional risk factors for severe disease  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 2</a>) or who are unvaccinated, after discussion of the benefits/risks and drug-drug interaction potential. We also provide it to patients who request therapy but have no risk factors for severe disease other than pregnancy. Limited supplies may warrant prioritization of COVID-19-specific therapy to those at the highest risk of severe disease using the tiered approach shown in the table  (<a class="graphic graphic_table graphicRef134702" href="/z/d/graphic/134702.html" rel="external">table 10</a>). A detailed discussion of COVID-19 specific therapies is available separately. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'</a>.)</p><p>In the United States, treatment of confirmed cases with <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> (preferred) or <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">remdesivir</a> is initiated as soon as possible after symptom onset. The maximum allowable time window for administration varies from 5 to 7 days after symptom onset, depending on the drug. The choice depends upon local availability, ease of prompt access to treatment, susceptibility to prevalent viral variants, ease of administration, safety during pregnancy and lactation (discussed in the following bulleted sections), and specific patient factors (eg, comorbid conditions, vaccination status, number and severity of risk factors for severe disease, and potential drug-drug interactions [eg, nirmatrelvir-ritonavir]). </p><p>Previously, monoclonal antibodies were also an option; however, they are not active against increasingly prevalent new Omicron variants worldwide (eg, BQ1.1)  (<a class="graphic graphic_table graphicRef131216" href="/z/d/graphic/131216.html" rel="external">table 11</a>). (See <a class="local">'Therapies of limited or uncertain benefit'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nirmatrelvir-ritonavir</strong> – <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">Nirmatrelvir-ritonavir</a> is approved for use in adults in the United States, including for pregnant patients. The dose is 300 mg nirmatrelvir (two 150 mg tablets) with one 100 mg <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> tablet taken together orally twice daily for five days. It should be initiated as soon as possible following COVID-19 diagnosis and within five days of symptom onset (symptom onset is day 0), particularly in patients with additional risk factors. Limited data in human pregnancies are available, but reassuring of safety and efficacy [<a href="#rid42">42,43</a>]. Minimal reproductive safety data from animal studies are available for nirmatrelvir (eg, reduced fetal body weights in rabbits when exposed to doses 10-fold higher and for a longer proportion of gestational days than authorized human maternal doses, which was attributed to lower maternal gestational body weight gain) [<a href="#rid44">44</a>]. However, extensive data are available for ritonavir in patients with HIV and no increased risk of overall teratogenic effects was observed following first-trimester exposure.</p><p></p><p class="bulletIndent1">Potential drug interactions are a particular concern in patients taking <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> (eg, in postpartum patients, ergot derivatives should be avoided and opioids used with caution). Consult a reliable prescribing reference to determine if nirmatrelvir-ritonavir use is appropriate or if risk can be safely mitigated with alteration of the patient's medication regimen. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Nirmatrelvir-ritonavir as preferred therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remdesivir</strong> – The need for IV administration daily for three days (200 mg IV on day 1, followed by 100 mg IV daily on days 2 and 3) is a disadvantage in outpatients. It should be initiated as soon as possible following COVID-19 diagnosis and within seven days of symptom onset. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Remdesivir'</a>.)</p><p></p><p class="bulletIndent1">Pregnancy considerations are addressed above. (See <a class="local">'COVID-19-specific treatments'</a> above.) </p><p></p><p>If <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> or <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">remdesivir</a> is unavailable or inappropriate, high-titer convalescent plasma is an option for COVID-19-specific therapy for symptomatic outpatients (especially those who are immunocompromised) with risk for progression to severe disease. High-titer convalescent plasma requires processes for collection, screening, and quantification, which may not be widely available. For logistical reasons and because of a growing body of evidence that COVID-19 convalescent plasma is not effective in late-stage disease, some blood centers have stopped collecting it, while others have intermittently continued collection as successive viral variants have emerged. (See  <a class="medical medical_review" href="/z/d/html/128321.html" rel="external">"COVID-19: Convalescent plasma and hyperimmune globulin"</a>.)</p><p>Safety and efficacy during pregnancy have not been evaluated in clinical trials; however, pathogen-specific immunoglobulins have been administered safely during pregnancy to prevent maternal varicella zoster virus and rabies virus infections and in trials to reduce symptomatic congenital cytomegalovirus (CMV) infection in offspring of mothers with primary CMV infection [<a href="#rid45">45</a>]. Pregnancy-related physiologic immunomodulation should not affect the decision to use COVID-19 convalescent plasma [<a href="#rid46">46</a>]. </p><p class="bulletIndent1">The maximum allowable time window for the transfusion in outpatients is within nine days of symptom onset. Treatment in late disease is not beneficial. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'High-titer convalescent plasma'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Limited role for antibody-based therapies (monoclonal antibodies and convalescent plasma)'</a>.)</p><p></p><p class="headingAnchor" id="H3250910215"><span class="h2">Therapies of limited or uncertain benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="134694" href="/z/d/drug information/134694.html" rel="external">Molnupiravir</a> is a nucleoside analogue that inhibits SARS-CoV-2 replication by viral mutagenesis. It has an EUA for treatment of mild to moderate COVID-19 in nonpregnant adults at risk for progression to severe disease. Molnupiravir reduces the time to recovery, but studies do not demonstrate efficacy against hospitalization or death. Because of its mechanism of action [<a href="#rid47">47</a>], possible adverse effects on the developing fetus and placenta are a concern. It is generally <strong>not</strong> recommended for pregnant patients due to concerns about instances of embryofetal lethality, teratogenicity, and reduced fetal growth in animal studies at exposures higher than expected with the recommended human dose. However, when other therapies are not available (eg, <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a>), pregnant people with COVID-19 who are at high risk of progressing to severe disease, especially those beyond the time of embryogenesis (ie, &gt;10 weeks' gestation), may reasonably choose molnupiravir therapy after being fully informed of the risks [<a href="#rid48">48</a>]. The discussion of the risks and benefits and the patient's choice should be documented. The manufacturer advises nonpregnant individuals of childbearing potential to use effective contraception correctly and consistently, as applicable, during treatment and for four days after the last dose [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">A registry to monitor pregnancy outcomes in individuals exposed to <a class="drug drug_general" data-topicid="134694" href="/z/d/drug information/134694.html" rel="external">molnupiravir</a> during pregnancy has been created. The prescribing healthcare provider is supposed to document that a pregnant individual was made aware of this registry (at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid-pr.pregistry.com%2F&amp;token=GDOHlJesKJxD%2BqMepjAIW97553mdzUo4d3gxsoN6nRidj%2FSj8vkByw%2BZ5kbec909&amp;TOPIC_ID=134827" target="_blank">registry website</a> or 1-800-616-3791).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-SARS-CoV-2 monoclonal antibodies</strong> – The choice of monoclonal antibody depends on the variant prevalent in the community, which has become a limiting factor since many variants are not susceptible to any of these agents  (<a class="graphic graphic_table graphicRef131216" href="/z/d/graphic/131216.html" rel="external">table 11</a>). </p><p></p><p class="bulletIndent1">Pregnancy implications of anti-SARS-CoV-2 monoclonal antibody therapy are not well defined, but they appear to reduce the risk of severe disease when active against prevalent variants and no significant adverse maternal or perinatal outcomes have been noted [<a href="#rid35">35,50-54</a>]. Humanized monoclonal antibodies (I<sub>g</sub>G1) cross the placenta beginning as early as 13 weeks of gestation, with increasing transport as the pregnancy progresses and the largest amount transferred in the third trimester [<a href="#rid55">55</a>]. A concern is that the transferred antibody may affect immune responses in utero in the exposed fetus. Nonclinical reproductive toxicity studies have not been performed, and there is minimal information regarding whether the potential transfer of these drugs provides any treatment benefit or risk to the developing fetus.</p><p></p><p>Additional information on drugs of limited or uncertain benefit and drugs that are not recommended is available separately. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies that we do not recommend'</a>.)</p><p class="headingAnchor" id="H1033312129"><span class="h1">RECOVERING PATIENTS</span></p><p class="headingAnchor" id="H3855978661"><span class="h2">Discontinuation of infection precautions</span><span class="headingEndMark"> — </span>Guidelines for patients in the community setting are shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef139926" href="/z/d/graphic/139926.html" rel="external">algorithm 2</a>) and guidelines for patients in the hospital setting are shown in the table  (<a class="graphic graphic_table graphicRef127962" href="/z/d/graphic/127962.html" rel="external">table 9</a>), and discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p class="headingAnchor" id="H242227602"><span class="h2">Time to recovery</span><span class="headingEndMark"> — </span>The time to recovery from COVID-19 is highly variable and depends on age and preexisting comorbidities in addition to illness severity. Individuals with mild infection are expected to recover relatively quickly (eg, within two weeks) whereas many individuals with severe disease have a longer time to recovery (eg, two to three months). The most common persistent symptoms include fatigue, dyspnea, chest pain, cough, and cognitive deficits.</p><p class="headingAnchor" id="H80647251"><span class="h2">Prenatal care and follow-up after recovery</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial follow-up</strong> – Hospitalized patients with COVID-19 ideally should have outpatient follow-up through telehealth or an in-person visit within one week but no later than two to three weeks after discharge from the hospital. They should call their provider if they develop new or worsening symptoms. Follow-up medical care is similar to that in nonpregnant patients, of whom up to 10 to 30 percent require rehospitalization. (See  <a class="medical medical_review" href="/z/d/html/129312.html" rel="external">"COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID")"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Post-discharge management'</a>.)</p><p></p><p class="bulletIndent1">Persistent physical symptoms following acute COVID-19 are common in adults, even after mild illness  (<a class="graphic graphic_table graphicRef130356" href="/z/d/graphic/130356.html" rel="external">table 12</a>). These symptoms are similar to the syndrome experienced by patients recovering from other critical illnesses and known as post-intensive care syndrome (PICS). PICS is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/88330.html" rel="external">"Post-intensive care syndrome (PICS) in adults: Clinical features and diagnostic evaluation"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal care</strong> – Prenatal care in asymptomatic and recovering/recovered patients is mostly routine. The risk of preterm birth in patients with resolved asymptomatic or symptomatic antepartum infection generally appears to be similar to that in those without infection; however, two studies reported that patients with first- or second-trimester COVID-19 experienced a modest increase in risk of adverse pregnancy outcome (eg, preterm birth, perinatal death, hypertensive disorders of pregnancy) later in pregnancy [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obstetric ultrasound</strong> – In the absence of robust data, pregnant persons with confirmed infection probably should have at least one ultrasound assessment of fetal growth, scheduled in the third trimester (eg, 30 to 32 weeks) or at least 14 days after symptom resolution or &gt;21 days from prior fetal biometry ultrasound, depending on timing of maternal infection. For those with first- or early second-trimester infection, the standard fetal anatomy scan at 18 to 23 weeks of gestation is performed.</p><p></p><p class="bulletIndent2">Development of fetal growth restriction is a theoretic concern and has been described with other SARS infections [<a href="#rid58">58,59</a>]. The very limited COVID-19-specific data on fetal growth after maternal infection are reassuring [<a href="#rid60">60-62</a>]. Although significant placental histopathologic changes are not universally present, suboptimal fetal growth due to placental insufficiency is plausible because maternal COVID-19 has been associated with vascular and inflammatory placental lesions, which appear to persist after recovery [<a href="#rid63">63-65</a>]. These lesions, termed SARS placentitis, could be caused by COVID-19-related coagulopathy, placental hypoxia during the acute maternal illness, placental viral infection, or a combination of these factors. (See  <a class="medical medical_review" href="/z/d/html/2284.html" rel="external">"Placental development and physiology", section on 'SARS-CoV-2'</a> and  <a class="medical medical_review" href="/z/d/html/129846.html" rel="external">"COVID-19: Intrapartum and postpartum issues", section on 'Placenta'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal surveillance</strong> – Antenatal fetal testing (nonstress test, biophysical profile) is typically reserved for standard obstetric indications [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment", section on 'Indications for fetal assessment'</a>.)</p><p></p><p class="headingAnchor" id="H2502219566"><span class="h1">TIMING OF DELIVERY</span><span class="headingEndMark"> — </span>Timing of delivery is individualized based on severity of COVID-19 infection, maternal status, concurrent disorders, gestational age, and shared decision-making with the patient or health care proxy.</p><p>Postnatal transmission in the delivery room is not a major concern because the risk is very low in the setting of infection control. It should be noted that maternal antibody production and, in turn, passive newborn immunity may not have had time to develop when maternal symptoms are acute. Maternal immunoglobulin G (IgG) levels increase soon after the maternal infection and peak &gt;30 days after onset of symptoms [<a href="#rid67">67</a>]. High placental transfer efficiency is achieved when infection onset is at least 60 days prior to birth [<a href="#rid68">68</a>]; however, the factors affecting transplacental antibody transfer, such as disease severity, have not been clearly elucidated [<a href="#rid67">67,69,70</a>].</p><p class="headingAnchor" id="H3248372729"><span class="h2">Patients with severe or critical COVID-19</span><span class="headingEndMark"> — </span>For patients who are severely ill, timing of delivery is individualized as multiple maternal and fetal factors must be considered, including [<a href="#rid1">1,71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Gestational age and plans for neonatal resuscitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severity of hypoxemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rate of disease progression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Response to escalating therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results of tests of fetal well-being</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whether a course of antenatal corticosteroids has been completed (for pregnancies between 23 and 34 weeks of gestation)</p><p></p><p>In general, we deliver pregnancies in which fetal testing suggests compromise (eg, bradycardia or repetitive late decelerations), and standard in utero resuscitative measures are unsuccessful, and the fetus is a candidate for neonatal resuscitation (if required), as long as delivery is unlikely to compromise a critically ill mother.</p><p>Maternal indications for delivery are more complicated. We avoid delivery in patients with oxygen saturation (SpO<sub>2</sub>) ≥95 percent. In patients with ongoing hypoxemia, timing of delivery is based on the factors described above. We have a low threshold for delivering pregnancies that have reached at least 32 to 34 weeks of gestation when the mother's disease is worsening. For pregnancies above the lower limit of viability but less than 30 to 32 weeks of gestation, the threshold for delivery is higher, such that as long as maternal health is not jeopardized by continuing the pregnancy, we avoid delivery because of the fetal benefits of prolonging the gestation. Decision-making in these cases must be individualized based on factors such as the specific gestational age and plans for neonatal resuscitation, severity of hypoxemia, rate of disease progression, response to escalating therapy, and comorbidities. However, refractory hypoxemic respiratory failure or worsening critical illness is generally an indication for delivery. In critically ill patients, although the stress of delivery could exacerbate the maternal condition and most ventilatory parameters associated with mortality in acute respiratory distress syndrome patients are not improved, limited data also suggest that delivery sometimes improves maternal hypoxemia [<a href="#rid15">15,72</a>]. In these cases, delivery reverses pregnancy-related increased oxygen consumption and reduced functional residual capacity, thus improving oxygenation [<a href="#rid73">73</a>]. Patients with excessive uterine distension because of multiple gestation or severe polyhydramnios in the third trimester would benefit most.</p><p class="headingAnchor" id="H3592035792"><span class="h2">Patients with nonsevere (or asymptomatic) COVID-19</span><span class="headingEndMark"> — </span>A positive test for COVID-19 is not a reason to postpone a planned delivery.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with nonsevere (or asymptomatic) COVID-19 at ≥39 weeks of gestation,</strong> delivery can be considered to decrease the risk of worsening maternal status before the onset of spontaneous labor [<a href="#rid8">8</a>]; however, most patients do not go on to develop severe COVID-19 [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Patients who had planned a week 39 induction of labor may proceed with the induction, if resources permit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most patients &lt;39 weeks with COVID-19 and nonsevere (or asymptomatic) illness who have no medical/obstetric indications for prompt delivery</strong>, intervention is not indicated; ideally, birth will occur sometime after recovery. Induction and cesarean birth are performed for standard obstetric indications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most patients &lt;39 weeks with COVID-19 and nonsevere (or asymptomatic) illness who also have medical/obstetric complications</strong> (eg, prelabor rupture of membranes, preeclampsia, pregestational diabetes), the timing of delivery is, in general, determined by usual protocols for the specific medical/obstetric disorder. Induction of labor or cesarean birth performed for appropriate medical/obstetric indications should <strong>not</strong> be postponed or rescheduled in such patients.</p><p></p><p class="headingAnchor" id="H712781728"><span class="h1">ROUTE OF DELIVERY, INTRAPARTUM AND POSTPARTUM MANAGEMENT</span><span class="headingEndMark"> — </span>Route of delivery, management of labor and delivery, and postpartum maternal and infant care are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/129846.html" rel="external">"COVID-19: Intrapartum and postpartum issues"</a>.)</p><p class="headingAnchor" id="H3196178900"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H1950747827"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The initial evaluation (by telehealth and/or in person) of patients with COVID-19 should focus on assessment of symptoms (eg, types, duration, severity) and risk factors for severe illness  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 2</a>). (See <a class="local">'Initial evaluation of symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triage</strong> – Inpatient care is generally required for patients with respiratory compromise (see <a class="local">'Candidates for hospitalization'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oxygen saturation (SpO<sub>2</sub>) &lt;94 percent on room air</p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory rate &gt;30 breaths/minute</p><p class="bulletIndent2"><span class="glyph">•</span>Pressure of oxygen (PaO<sub>2</sub>)/fraction of inspired oxygen (FiO<sub>2</sub>) &lt;300 mmHg</p><p class="bulletIndent2"><span class="glyph">•</span>Lung infiltrates &gt;50 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inpatient management</strong> – Management of inpatients with severe COVID-19 includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible empiric treatment for influenza or bacterial pneumonia. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Empiric treatment for influenza during influenza season'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Empiric treatment for bacterial pneumonia in selected patients'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevention of venous thromboembolism (VTE). (See <a class="local">'Venous thromboembolism prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintaining maternal peripheral SpO<sub>2</sub> at ≥95 percent. (See <a class="local">'Target SpO2'</a> above and <a class="local">'Respiratory support'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for maternal treatment and, in pregnancies at 23 to 34 weeks, to induce fetal maturation. In patients with diabetes, glucose levels should be monitored and insulin dose adjusted to maintain euglycemia. (See <a class="local">'Use of dexamethasone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of COVID-19-specific therapy  (<a class="graphic graphic_algorithm graphicRef134578" href="/z/d/graphic/134578.html" rel="external">algorithm 1</a>). (See <a class="local">'COVID-19-specific treatments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal monitoring. Initiation and frequency depend on gestational age, stability of maternal vital signs and oxygenation, other maternal comorbidities, and discussions with the patient and family that consider the possibly increased risks of stillbirth and perinatal morbidities in the absence of testing. (See <a class="local">'Fetal monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient management</strong> – Most patients are asymptomatic or have nonsevere COVID-19 and can be managed at home. Outpatients should be followed closely for progression to severe or critical disease and given instructions for infection control, symptom management, warning symptoms, and obstetric follow-up (at least once within two weeks of COVID-19 diagnosis). (See <a class="local">'Home care'</a> above and <a class="local">'When to call the provider'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>COVID-19-specific therapy – Pregnant patients are candidates for COVID-19-specific therapy, if available, especially if they have comorbidities in addition to pregnancy  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 2</a>) or are unvaccinated. The benefit/risk balance is unclear in vaccinated patients when pregnancy is the only risk factor for severe disease. (See <a class="local">'Use of antiviral therapy'</a> above.)</p><p></p><p class="bulletIndent2">If COVID-19-specific therapy is used, <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> (preferred) or <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">remdesivir</a> is initiated as soon as possible after symptom onset. (See <a class="local">'Use of antiviral therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guidelines for use and discontinuation of isolation are shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef139926" href="/z/d/graphic/139926.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of delivery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In patients with severe COVID-19,</strong> we deliver pregnancies in which fetal testing suggests compromise (eg, bradycardia or repetitive late decelerations), and standard in utero resuscitative measures are unsuccessful, and the fetus is a candidate for neonatal resuscitation (if required), as long as delivery is unlikely to compromise a critically ill mother.</p><p></p><p class="bulletIndent2">Maternal indications for delivery are more complicated. We avoid delivery in patients with SpO<sub>2</sub> ≥95 percent. In patients with ongoing hypoxemia, we have a low threshold for delivering pregnancies that have reached at least 32 to 34 weeks of gestation when the mother's condition is worsening. For pregnancies above the lower limit of viability but less than 30 to 32 weeks of gestation, the threshold for delivery is higher, such that as long as maternal health is not jeopardized by continuing the pregnancy, we avoid delivery because of the fetal benefits of prolonging the gestation. Although decision-making in these cases must be individualized based on multiple factors, refractory hypoxemic respiratory failure or worsening critical illness is generally an indication for delivery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In patients with nonsevere COVID-19</strong>, timing of delivery is based on standard obstetric indications. COVID-19 is not a reason to postpone a planned delivery. (See <a class="local">'Patients with nonsevere (or asymptomatic) COVID-19'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Donders F, Lonnée-Hoffmann R, Tsiakalos A, et al. ISIDOG Recommendations Concerning COVID-19 and Pregnancy. Diagnostics (Basel) 2020; 10.</a></li><li class="breakAll">acog.org (Accessed on July 13, 2021).</li><li><a class="nounderline abstract_t">Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19. Ultrasound Obstet Gynecol 2020; 55:593.</a></li><li><a class="nounderline abstract_t">Buonsenso D, Raffaelli F, Tamburrini E, et al. Clinical role of lung ultrasound for diagnosis and monitoring of COVID-19 pneumonia in pregnant women. Ultrasound Obstet Gynecol 2020; 56:106.</a></li><li><a class="nounderline abstract_t">Biancolin SE, Dos Santos Fernandes H, Sawamura MVY, et al. Lung ultrasound versus chest computed tomography for pregnant inpatients with COVID-19. J Clin Ultrasound 2023; 51:54.</a></li><li class="breakAll">NIH. COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/search/?q=admit (Accessed on March 07, 2023).</li><li><a class="nounderline abstract_t">Poon LC, Yang H, Dumont S, et al. ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update. Ultrasound Obstet Gynecol 2020; 55:848.</a></li><li class="breakAll">Publications &amp; Clinical Guidance. Society for Maternal Fetal Medicine. Updated June, 2022. Available online at: https://www.smfm.org/covidclinical (Accessed on February 17, 2023).</li><li class="breakAll">World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected” interim guidance 27 May 2020.</li><li><a class="nounderline abstract_t">Eid J, Stahl D, Costantine MM, Rood KM. Oxygen saturation in pregnant individuals with COVID-19: time for re-appraisal? Am J Obstet Gynecol 2022; 226:813.</a></li><li><a class="nounderline abstract_t">Tolcher MC, McKinney JR, Eppes CS, et al. Prone Positioning for Pregnant Women With Hypoxemia Due to Coronavirus Disease 2019 (COVID-19). Obstet Gynecol 2020; 136:259.</a></li><li class="breakAll">Pacheco LD, Saad A. Ventilator management in critical illness. In: Critical Care Obstetrics, 6th ed, Phelan JP, Pacheco LD, Foley MR, et al (Eds), Wiley-Blackwell, 2018.</li><li><a class="nounderline abstract_t">Webster CM, Smith KA, Manuck TA. Extracorporeal membrane oxygenation in pregnant and postpartum women: a ten-year case series. Am J Obstet Gynecol MFM 2020; 2:100108.</a></li><li><a class="nounderline abstract_t">Osmundo GS Jr, Paganotti CF, da Costa RA, et al. Prone Positioning: A Safe and Effective Procedure in Pregnant Women Presenting with Severe Acute Respiratory Distress Syndrome. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Vasquez DN, Giannoni R, Salvatierra A, et al. Ventilatory Parameters in Obstetric Patients With COVID-19 and Impact of Delivery: A Multicenter Prospective Cohort Study. Chest 2023; 163:554.</a></li><li><a class="nounderline abstract_t">Barrantes JH, Ortoleva J, O'Neil ER, et al. Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. ASAIO J 2021; 67:132.</a></li><li><a class="nounderline abstract_t">Shih E, DiMaio JM, Squiers JJ, et al. Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients. Am J Obstet Gynecol MFM 2022; 4:100537.</a></li><li><a class="nounderline abstract_t">Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396:1071.</a></li><li><a class="nounderline abstract_t">Yin O, Richley M, Hadaya J, et al. Extracorporeal membrane oxygenation in pregnancy: a bridge to delivery and pulmonary recovery for COVID-19-related severe respiratory failure. Am J Obstet Gynecol 2022; 226:571.</a></li><li><a class="nounderline abstract_t">Shamshirsaz AA, Byrne JJ, Ramsey PS, et al. Extracorporeal Membrane Oxygenation in Pregnant and Postpartum Women With Critical Coronavirus Disease 2019 (COVID-19) Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis. Obstet Gynecol 2024; 143:219.</a></li><li><a class="nounderline abstract_t">Bruno AM, Horns JJ, Metz TD. Coronavirus Disease 2019 (COVID-19) and Venous Thromboembolism During Pregnancy and Postpartum. Obstet Gynecol 2024; 143:139.</a></li><li><a class="nounderline abstract_t">Jering KS, Claggett BL, Cunningham JW, et al. Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. JAMA Intern Med 2021; 181:714.</a></li><li><a class="nounderline abstract_t">Metz TD, Clifton RG, Hughes BL, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol 2021; 137:571.</a></li><li><a class="nounderline abstract_t">Servante J, Swallow G, Thornton JG, et al. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth 2021; 21:108.</a></li><li><a class="nounderline abstract_t">Metz TD, Clifton RG, Hughes BL, et al. Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications. JAMA 2022; 327:748.</a></li><li><a class="nounderline abstract_t">Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19). Obstet Gynecol 2020; 136:823.</a></li><li class="breakAll">WHO Therapeutic Guidance: Review of current recommendations and application in pregnancy https://cdn.who.int/media/docs/default-source/health-care-readiness---post-covid-19-condition/4_who-therapeutic-guidelines_review-of-current-recommendations-and-application-in-pregnancy_beverley-hunt.pdf.</li><li class="breakAll">Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients. http://www.isrctn.com/ISRCTN83971151 (Accessed on July 20, 2020).</li><li class="breakAll">RECOVERY. Randomised Evaluation of COVID-19 Therapy. https://www.recoverytrial.net/ (Accessed on July 20, 2020).</li><li><a class="nounderline abstract_t">Jorgensen SC, Tabbara N, Burry L. A review of COVID-19 therapeutics in pregnancy and lactation. Obstet Med 2022; 15:225.</a></li><li><a class="nounderline abstract_t">Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381:2293.</a></li><li><a class="nounderline abstract_t">Costanzo G, Firinu D, Losa F, et al. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2020; 12:1759720X19899296.</a></li><li class="breakAll">https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/ (Accessed on April 07, 2022).</li><li><a class="nounderline abstract_t">Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033.</a></li><li><a class="nounderline abstract_t">Jorgensen SCJ, Lapinsky SE. Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review. Clin Microbiol Infect 2022; 28:51.</a></li><li class="breakAll">https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/.</li><li><a class="nounderline abstract_t">Karakaş Ö, Erden A, Ünlü S, et al. Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19? Women Health 2021; 61:872.</a></li><li><a class="nounderline abstract_t">Huntley BJF, Huntley ES, Di Mascio D, et al. Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstet Gynecol 2020; 136:303.</a></li><li><a class="nounderline abstract_t">Schell RC, Macias DA, Garner WH, et al. Examining the impact of trimester of diagnosis on COVID-19 disease progression in pregnancy. Am J Obstet Gynecol MFM 2022; 4:100728.</a></li><li><a class="nounderline abstract_t">Yao R, Martin CB, Haase VS, et al. Initial clinical characteristics of gravid severe acute respiratory syndrome coronavirus 2-positive patients and the risk of progression to severe coronavirus disease 2019. Am J Obstet Gynecol MFM 2021; 3:100365.</a></li><li><a class="nounderline abstract_t">Alcover N, Regiroli G, Benachi A, et al. Systematic review and synthesis of stillbirths and late miscarriages following SARS-CoV-2 infections. Am J Obstet Gynecol 2023; 229:118.</a></li><li><a class="nounderline abstract_t">Loza A, Farias R, Gavin N, et al. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol 2022; 140:447.</a></li><li><a class="nounderline abstract_t">Toure BB, Panakam A, Johns SL, et al. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol 2024; 143:273.</a></li><li><a class="nounderline abstract_t">Catlin NR, Bowman CJ, Campion SN, et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Reprod Toxicol 2022; 108:56.</a></li><li class="breakAll">https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/convalescent-plasma/ (Accessed on May 25, 2022).</li><li class="breakAll">COVID-19 Convalescent Plasma https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/ (Accessed on February 22, 2023).</li><li><a class="nounderline abstract_t">Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 2021; 28:740.</a></li><li class="breakAll">NIH COVID-19 Treatment Guidelines. The COVID-19 Treatment Guidelines Panel's Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19 https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/ (Accessed on January 05, 2022).</li><li class="breakAll">US Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio (molnupiravir) capsules. Available at: https://www.fda.gov/media/155054/download (Accessed on October 26, 2023).</li><li><a class="nounderline abstract_t">Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 2016; 46:238.</a></li><li><a class="nounderline abstract_t">Pham-Huy A, Top KA, Constantinescu C, et al. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021; 193:E1129.</a></li><li><a class="nounderline abstract_t">Chang MH, Cowman K, Guo Y, et al. A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregnancy. Am J Obstet Gynecol 2022; 226:743.</a></li><li><a class="nounderline abstract_t">Eid J, Abdelwahab M, Williams H, et al. Outpatient Use of Monoclonal Antibodies in Pregnant Individuals With Mild or Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol 2022; 140:74.</a></li><li><a class="nounderline abstract_t">McCreary EK, Lemon L, Megli C, et al. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study. Ann Intern Med 2022; 175:1707.</a></li><li><a class="nounderline abstract_t">Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012:985646.</a></li><li><a class="nounderline abstract_t">Piekos SN, Roper RT, Hwang YM, et al. The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study. Lancet Digit Health 2022; 4:e95.</a></li><li><a class="nounderline abstract_t">Hughes BL, Sandoval GJ, Metz TD, et al. First- or second-trimester SARS-CoV-2 infection and subsequent pregnancy outcomes. Am J Obstet Gynecol 2023; 228:226.e1.</a></li><li><a class="nounderline abstract_t">Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191:292.</a></li><li><a class="nounderline abstract_t">Ng WF, Wong SF, Lam A, et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology 2006; 38:210.</a></li><li><a class="nounderline abstract_t">Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2:100107.</a></li><li><a class="nounderline abstract_t">Mullins E, Hudak ML, Banerjee J, et al. Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound Obstet Gynecol 2021; 57:573.</a></li><li><a class="nounderline abstract_t">Narang K, Miller M, Trinidad C, et al. Impact of asymptomatic and mild COVID-19 infection on fetal growth during pregnancy. Eur J Obstet Gynecol Reprod Biol 2023; 281:63.</a></li><li><a class="nounderline abstract_t">Suhren JT, Meinardus A, Hussein K, Schaumann N. Meta-analysis on COVID-19-pregnancy-related placental pathologies shows no specific pattern. Placenta 2022; 117:72.</a></li><li><a class="nounderline abstract_t">Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2021; 3:100468.</a></li><li><a class="nounderline abstract_t">Boyraz B, James K, Hornick JL, Roberts DJ. Placental pathology from COVID-19-recovered (nonacute) patients. Hum Pathol 2022; 125:18.</a></li><li class="breakAll">https://smfm.org (Accessed on November 24, 2020).</li><li><a class="nounderline abstract_t">Kubiak JM, Murphy EA, Yee J, et al. Severe acute respiratory syndrome coronavirus 2 serology levels in pregnant women and their neonates. Am J Obstet Gynecol 2021; 225:73.e1.</a></li><li><a class="nounderline abstract_t">Song D, Prahl M, Gaw SL, et al. Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: prospective cohort study. BMJ Open 2021; 11:e053036.</a></li><li><a class="nounderline abstract_t">Edlow AG, Li JZ, Collier AY, et al. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open 2020; 3:e2030455.</a></li><li><a class="nounderline abstract_t">Joseph NT, Dude CM, Verkerke HP, et al. Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Obstet Gynecol 2021; 138:189.</a></li><li><a class="nounderline abstract_t">Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet 2020; 149:130.</a></li><li><a class="nounderline abstract_t">Péju E, Belicard F, Silva S, et al. Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study. Intensive Care Med 2022; 48:1185.</a></li><li><a class="nounderline abstract_t">Stephens AJ, Barton JR, Bentum NA, et al. General Guidelines in the Management of an Obstetrical Patient on the Labor and Delivery Unit during the COVID-19 Pandemic. Am J Perinatol 2020; 37:829.</a></li><li><a class="nounderline abstract_t">Hill J, Patrick HS, Ananth CV, et al. Obstetrical outcomes and follow-up for patients with asymptomatic COVID-19 at delivery: a multicenter prospective cohort study. Am J Obstet Gynecol MFM 2021; 3:100454.</a></li></ol></div><div id="topicVersionRevision">Topic 134827 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338645" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ISIDOG Recommendations Concerning COVID-19 and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338645" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ISIDOG Recommendations Concerning COVID-19 and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207208" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : How to perform lung ultrasound in pregnant women with suspected COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337795" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical role of lung ultrasound for diagnosis and monitoring of COVID-19 pneumonia in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36639846" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lung ultrasound versus chest computed tomography for pregnant inpatients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36639846" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lung ultrasound versus chest computed tomography for pregnant inpatients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356590" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356590" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356590" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34922921" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oxygen saturation in pregnant individuals with COVID-19: time for re-appraisal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32516274" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prone Positioning for Pregnant Women With Hypoxemia Due to Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32516274" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prone Positioning for Pregnant Women With Hypoxemia Due to Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835205" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Extracorporeal membrane oxygenation in pregnant and postpartum women: a ten-year case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36560592" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prone Positioning: A Safe and Effective Procedure in Pregnant Women Presenting with Severe Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36257474" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ventilatory Parameters in Obstetric Patients With COVID-19 and Impact of Delivery: A Multicenter Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33229971" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34813975" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32987008" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34922925" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extracorporeal membrane oxygenation in pregnancy: a bridge to delivery and pulmonary recovery for COVID-19-related severe respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37944145" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Extracorporeal Membrane Oxygenation in Pregnant and Postpartum Women With Critical Coronavirus Disease 2019 (COVID-19) Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38096554" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coronavirus Disease 2019 (COVID-19) and Venous Thromboembolism During Pregnancy and Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449067" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33560778" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33546624" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35129581" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32769659" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32769659" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32769659" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32769659" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36514791" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A review of COVID-19 therapeutics in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774950" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32071617" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Baricitinib exposure during pregnancy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32071617" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Baricitinib exposure during pregnancy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192578" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : COVID-19: consider cytokine storm syndromes and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34438068" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34438068" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551674" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32516273" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35995369" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Examining the impact of trimester of diagnosis on COVID-19 disease progression in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819676" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Initial clinical characteristics of gravid severe acute respiratory syndrome coronavirus 2-positive patients and the risk of progression to severe coronavirus disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36706855" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Systematic review and synthesis of stillbirths and late miscarriages following SARS-CoV-2 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36356238" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37963387" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101563" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101563" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101563" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34381216" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34381216" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34381216" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346577" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34312166" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The use and impact of monoclonal antibody biologics during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35074337" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35849458" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outpatient Use of Monoclonal Antibodies in Pregnant Individuals With Mild or Moderate Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375150" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22235228" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : IgG placental transfer in healthy and pathological pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35034863" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35970201" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : First- or second-trimester SARS-CoV-2 infection and subsequent pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295381" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16753741" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32292902" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620113" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36549070" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of asymptomatic and mild COVID-19 infection on fetal growth during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34773743" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Meta-analysis on COVID-19-pregnancy-related placental pathologies shows no specific pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34425296" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35405186" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Placental pathology from COVID-19-recovered (nonacute) patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35405186" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Placental pathology from COVID-19-recovered (nonacute) patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497654" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Severe acute respiratory syndrome coronavirus 2 serology levels in pregnant women and their neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34234001" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351086" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33910220" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196655" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35978137" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32344441" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : General Guidelines in the Management of an Obstetrical Patient on the Labor and Delivery Unit during the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34375750" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Obstetrical outcomes and follow-up for patients with asymptomatic COVID-19 at delivery: a multicenter prospective cohort study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
